Literature DB >> 24839894

A double-blinded, prospective study to define antigenemia and quantitative real-time polymerase chain reaction cutoffs to start preemptive therapy in low-risk, seropositive, renal transplanted recipients.

Elias David-Neto1, Ana H K Triboni, Flavio J Paula, Lucy S Vilas Boas, Clarisse M Machado, Fabiana Agena, Acram Z A Latif, Cecília S Alencar, Ligia C Pierrotti, William C Nahas, Helio H Caiaffa-Filho, Claudio S Pannuti.   

Abstract

BACKGROUND: Cytomegalovirus (CMV) disease occurs in 16% to 20% of low-risk, CMV-positive renal transplant recipients. The cutoffs for quantitative real-time polymerase chain reaction (qPCR) or phosphoprotein (pp65) antigenemia (pp65emia) for starting preemptive therapy have not been well established.
METHODS: We measured qPCR and pp65emia weekly from day 7 to day 120 after transplantation, in anti-CMV immunoglobulin G–positive donor and recipient pairs. Patients and physicians were blinded to the test results. Suspicion of CMV disease led to the order of new tests. In asymptomatic viremic patients, the highest pp65emia and qPCR values were used, whereas we considered the last value before diagnosis in those with CMV disease.
RESULTS: We collected a total of 1,481 blood samples from 102 adult patients. Seventeen patients developed CMV disease, 54 presented at least one episode of viremia that cleared spontaneously, and 31 never presented viremia. Five patients developed CMV disease after the end of the study period. The median (95% confidence interval) pp65emia and qPCR values were higher before CMV disease than during asymptomatic viremia (6 [9–82] vs. 3 [1–14] cells/10(6) cells; P<0.001 and 3,080 [1,263–15,605] vs. 258 [258–1,679] copies/mL; P=0.008, respectively). The receiver operating characteristic curve showed that pp65emia 4 cells/10(6) cells or greater showed a sensitivity and specificity to predict CMV disease of 69% and 81%, respectively (area, 0.769; P=0.001), with a positive predictive value of 37% and a negative predictive value of 93%. For qPCR 2,000 copies/mL or higher, the positive predictive value and negative predictive value were 57% and 91%, respectively (receiver operating characteristic area, 0.782; P=0.000).
CONCLUSION: With these cutoffs, both methods are appropriate for detecting CMV disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24839894     DOI: 10.1097/TP.0000000000000189

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  9 in total

1.  Cytomegalovirus Viral Load in Transplanted Patients Using the NeuMoDx™ (Qiagen) Automated System: A 1-Month Experience Feedback.

Authors:  Léa Luciani; Denis Mongin; Laetitia Ninove; Antoine Nougairède; Kevin Bardy; Céline Gazin; Remi N Charrel; Christine Zandotti
Journal:  Viruses       Date:  2021-08-16       Impact factor: 5.048

2.  Local evidence on the cytomegalovirus viral load threshold for preemptive treatment is welcome, and a comment on indirect effects.

Authors:  Lúcio R Requião-Moura
Journal:  J Bras Nefrol       Date:  2021 Oct-Dec

Review 3.  Cytomegalovirus infection in transplant recipients.

Authors:  Luiz Sergio Azevedo; Lígia Camera Pierrotti; Edson Abdala; Silvia Figueiredo Costa; Tânia Mara Varejão Strabelli; Silvia Vidal Campos; Jéssica Fernandes Ramos; Acram Zahredine Abdul Latif; Nadia Litvinov; Natalya Zaidan Maluf; Helio Hehl Caiaffa Filho; Claudio Sergio Pannuti; Marta Heloisa Lopes; Vera Aparecida dos Santos; Camila da Cruz Gouveia Linardi; Maria Aparecida Shikanai Yasuda; Heloisa Helena de Sousa Marques
Journal:  Clinics (Sao Paulo)       Date:  2015-07-01       Impact factor: 2.365

4.  Prevalence of cytomegalovirus disease in kidney transplant patients in an intensive care unit.

Authors:  Sanmya Danielle Rodrigues Dos Santos; Antonio Tonete Bafi; Flávio Geraldo Rezende de Freitas; Luciano César Pontes de Azevedo; Flávia Ribeiro Machado
Journal:  Rev Bras Ter Intensiva       Date:  2017 Oct-Dec

Review 5.  Colon perforation due to antigenemia-negative cytomegalovirus gastroenteritis after liver transplantation: A case report and review of literature.

Authors:  Takahiro Yokose; Hideaki Obara; Masahiro Shinoda; Yutaka Nakano; Minoru Kitago; Hiroshi Yagi; Yuta Abe; Yohei Yamada; Kentaro Matsubara; Go Oshima; Shutaro Hori; Sho Ibuki; Hisanobu Higashi; Yuki Masuda; Masanori Hayashi; Takehiko Mori; Miho Kawaida; Takumi Fujimura; Ken Hoshino; Kaori Kameyama; Tatsuo Kuroda; Yuko Kitagawa
Journal:  World J Gastroenterol       Date:  2019-04-21       Impact factor: 5.742

Review 6.  [Viral infections in urology].

Authors:  G Magistro; A Pilatz; P Schneede; L Schneidewind; F Wagenlehner
Journal:  Urologe A       Date:  2021-07-06       Impact factor: 0.639

7.  Clinical validation of an in-house quantitative real time PCR assay for cytomegalovirus infection using the 1st WHO International Standard in kidney transplant patients.

Authors:  Cassia F B Caurio; Odelta S Allende; Roger Kist; Kênya L Santos; Izadora C S Vasconcellos; Franciéli P Rozales; Daiane F Dalla Lana; Bruno M Praetzel; Ana Paula Alegretti; Alessandro C Pasqualotto
Journal:  J Bras Nefrol       Date:  2021 Oct-Dec

8.  Targeted preemptive therapy according to perceived risk of CMV infection after kidney transplantation.

Authors:  Cahue Henrique Pinto; Helio Tedesco-Silva; Claudia Rosso Felipe; Alexandra Nicolau Ferreira; Marina Cristelli; Laila Almeida Viana; Wilson Aguiar; José Medina-Pestana
Journal:  Braz J Infect Dis       Date:  2016-09-25       Impact factor: 3.257

9.  Clinical correlates of pp65 antigenemia monitoring in the first months of post kidney transplant in patients undergoing universal prophylaxis or preemptive therapy.

Authors:  Fabiana Rabe Carvalho; Rachel Ingrid Juliboni Cosendey; Cintia Fernandes Souza; Thalia Medeiros; Paulo Alexandre Menezes; Andrea Alice Silva; Jorge Reis Almeida; Jocemir Ronaldo Lugon
Journal:  Braz J Infect Dis       Date:  2016-11-23       Impact factor: 3.257

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.